Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
The experimental drug showed a promise in preventing Alzheimer’s disease for people with a greater risk of developing the disease.
This is said in a new study of Washington University medical school in St. Louis, where researchers conducted a clinical test of people with rare genetic mutations This almost “guarantees” the future development of Alzheimer, the press -release said.
The study included 73 people in the 30s, 40s and 50s, which have a mutation, which causes overproduction of amyloid in the brain.
Parkinson’s cases may double the world by 2050, shows the study
Amyloid, a protein that grows in the brain and can interfere with cognitive function, is one of the distinctive features of Alzheimer.
The experimental drug showed a promise in preventing Alzheimer’s disease for people with a greater risk of developing the disease. (Istock)
All participants did not (either very soft) cognitive decline, had Alzheimer’s family storyAnd they were for 15 years to 10 years after their expected age from the development of symptoms, the release said.
For 22 participants who received drugs called dumniab for eight years, their risk of symptoms was reduced in half – from 100% to 50% – the researchers say.
“What we know is something that can at least delay the occurrence of Alzheimer’s symptoms and give people more years old.”
“No effect was found in those who have only been treated for two or two years of treatment,” said the senior author of J. Bateman, Doctor of Medical Sciences, Charles F. and Joanna Knit -Professor of Neurology in the Washu Medicine, Fox News Digital.
The conclusions were published in the Lancet Neurology magazine on March 19.
For 22 participants who received drugs called dumniab for eight years, their risk of symptoms was reduced in half – from 100% to 50% – the researchers say. (Istock)
Duke, monoclonal antibodies intended for targeting and removing amyloid plaques in the brain, were in the development of Rosz in Switzerland and its branch of the United States, Genentech.
However, the development was stopped in 2023 after its own Rosh/Gentech Clinical trials It turned out that the drug does not correspond to its “main final point” to slow down the cognitive reduction of people with early symptomatic Alzheimer’s disease, the release reports.
A higher risk of dementia that is observed in women with a common health problem
“All this study was destined to develop Alzheimer’s disease, and some are not yet,” Bateman said in the release.
“We do not yet know how long they will be without symptoms, it is possible for several years, and maybe for decades. To give them the best opportunity to remain cognitively normal, we continued treatment with other antibodies in the hope that they would never develop the symptoms,” he continued.
I hope that if Alzheimer’s tests have similar results, prevention methods can be available for the total population, the researchers say. (Istock)
“What we know is what can at least delay the occurrence of Alzheimer’s symptoms and give people more years a healthy life“
I hope that when Alzheimer’s tests have similar results, prevention methods can be available for the wide population, Bateman believes.
The risk of dementia may increase at low level of vitamin
“I am very optimistic now, as this can be the first clinical testimony that it will become a prevention for people who risk Alzheimer’s disease,” he said. “In the near future we can delay the onset of Alzheimer’s millions.”
Howard Filit, Doctor of Medical Sciences, Co-founder and Chief Scientific Director of Alzheimer’s Drug Detection Fund in New York, noted that the study first shows that early treatment to cleanse the boards before symptoms may delay the onset of Alzheimer- “Looks.
Despite the fact that the dumbbells are no longer developed, the researchers evaluate other anti-amyloid drugs, recalls that Eli Lily-Kab is produced whether they can prevent Alzheimer’s disease. (Istock)
“We have entered the new era of Alzheimer’s research, where we can not only change the course of the disease, but also where prevention is possible therapeutic intervention“Filit, who did not participate in the study, said Fox News Digital.
Potential restrictions and risks
The research has several major restrictions, said Bateman Digital Fox News.
The number of people was limited due to the rare disease of Alzheimer caused by mutations, using external control, and the fact that the study began with smaller doses, he said.
Two Alzheimer’s two drugs help patients live independently at home for longer periods
“Many participants are still cognitively normal and close or past expected age, even after more than eight years of treatment, so the consequences may be greater and less in further treatment and subsequent actions,” Biteman said.
Researchers noted this Antamiloid medicine As it is shown, the dumniab causes anomalies associated with amyloid (ARIA).
Amyloid, a protein that grows in the brain and can interfere with cognitive function, is one of the distinctive features of Alzheimer. (Istock)
They appear when scanning the brain as “tiny blood spots in the brain or localized brain swelling“It is said in the issue.
Most of these side effects do not cause symptoms and are resolved without treatment, but in rare cases, aria can cause serious medical problems or may even be fatal.
This latest study found that 30% of participants survived ARIA, probably because of higher doses of the drug.
Despite the fact that the two participants had to stop the use of the dumniab because of the serious aria, there were no “dangerous for the life of side events and deaths,” the researchers noted.
“Overall, the security profile in the expansion was similar to the one that was in the original test and in other clinical trials of the dumniab,” they said.
Additional research required, experts agree
Dr. Chris Vercamen, certified by the Council of Internal Medicine, who specializes in Geriatrics and palliative assistanceHe said that while these initial conclusions are “encouraging”, additional studies on the impact of these drugs are needed.
“Great, randomized tests, including a variety of populations and persons with Alzheimer with a late start needed to check these early results and determine the full potential of these therapies,” said Vercammen, which is also a medical director in Remo Health in California, Fox NEWS Digital said. (He did not participate in a new study.)
Click here to get the Fox News app
“It is important to note that the design of this study was aimed at high -risk people at the preclinical stage, and therefore does not give sufficient data on the impact of these drugs on the next stage of Alzheimer.”
Filit added that this new study opens the door to further study the treatment of preclinic Alzheimer.
It has been shown that anti -amyloid drugs, such as dumbbells, cause amyloid visualization (ARIA), which appear on the brain scan as “tiny blood spots in the brain or localized brain edema”. (Istock)
“We look forward to seeing longitudinal data as well as further research around this approach,” he said Digital Fox News.
“These efforts make us step closer to our ultimate goal Prevent the disease Before you start. “
Click here to subscribe to our health newsletter
Despite the fact that the dumbbells are no longer developed, the researchers evaluate other anti-amyloid drugs, recalls that Eli Lily-Kab is produced whether they can prevent Alzheimer’s disease.
“This effort brings us closer to step closer to our ultimate goal of preventing the disease before the beginning of it.”
“These rare families with mutations may wish to participate in current trials,” said Bateman Digital Fox News.
“The senior common population may be interested in finding out what is Continuing the tests In people with amyloid plaques to check this approach to determine whether it is possible to prevent Alzheimer’s symptoms. “
For additional health articles visit www.foxnews.com/health
The study was mainly funded by the Alzheimer Association, the GR and the National Institute of Health (NIH).
Fox News Digital turned to Roche/Genentech for comments.
